Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LUNGNASDAQ:OFIXNASDAQ:PLSENASDAQ:SRDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLUNGPulmonx$2.75+1.5%$3.73$2.62▼$9.37$110.71M0.52308,144 shs294,202 shsOFIXOrthofix Medical$10.35-1.6%$12.14$10.25▼$20.73$405.52M0.8280,128 shs1.01 million shsPLSEPulse Biosciences$15.05+0.1%$16.98$9.70▼$25.00$1.01B1.63186,989 shs238,550 shsSRDXSurmodics$29.14+0.3%$28.72$26.00▼$42.44$416.68M1.33245,122 shs67,484 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLUNGPulmonx+1.48%-15.64%-17.66%-64.29%-53.35%OFIXOrthofix Medical-1.62%-9.05%-14.18%-38.76%-19.58%PLSEPulse Biosciences+0.07%-10.04%-12.14%-7.16%+32.02%SRDXSurmodics+0.31%+0.52%-1.15%-2.80%-30.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLUNGPulmonx3.5086 of 5 stars3.35.00.00.02.53.30.6OFIXOrthofix Medical2.8252 of 5 stars3.42.00.00.01.43.31.3PLSEPulse Biosciences1.3481 of 5 stars0.01.00.04.21.94.20.0SRDXSurmodics3.3881 of 5 stars3.33.00.03.40.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLUNGPulmonx 2.63Moderate Buy$11.53319.09% UpsideOFIXOrthofix Medical 2.75Moderate Buy$23.33125.44% UpsidePLSEPulse Biosciences 0.00N/AN/AN/ASRDXSurmodics 2.50Moderate Buy$43.0047.56% UpsideCurrent Analyst Ratings BreakdownLatest LUNG, OFIX, SRDX, and PLSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025OFIXOrthofix MedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/30/2025SRDXSurmodicsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLUNGPulmonx$83.79M1.32N/AN/A$2.17 per share1.27OFIXOrthofix Medical$799.49M0.51N/AN/A$13.07 per share0.79PLSEPulse Biosciences$700K1,446.31N/AN/A$1.87 per share8.05SRDXSurmodics$126.08M3.31$0.31 per share94.19$8.33 per share3.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)OFIXOrthofix Medical-$126M-$3.69N/AN/AN/A-17.78%-28.15%-16.51%8/5/2025 (Estimated)PLSEPulse Biosciences-$53.58MN/A0.00∞N/AN/A-68.44%-58.17%8/11/2025 (Estimated)SRDXSurmodics-$11.54M-$1.39N/A36.43N/A-16.34%-7.10%-4.77%7/30/2025 (Estimated)Latest LUNG, OFIX, SRDX, and PLSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PLSEPulse BiosciencesN/A-$0.25N/A-$0.25N/AN/A5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million4/30/2025Q2 2025SRDXSurmodics-$0.06-$0.13-$0.07-$0.36$32.23 million$28.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLUNGPulmonxN/AN/AN/AN/AN/AOFIXOrthofix MedicalN/AN/AN/AN/AN/APLSEPulse BiosciencesN/AN/AN/AN/AN/ASRDXSurmodicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLUNGPulmonx0.384.974.29OFIXOrthofix Medical0.382.711.50PLSEPulse BiosciencesN/A15.5815.58SRDXSurmodics0.275.143.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLUNGPulmonx91.04%OFIXOrthofix Medical89.76%PLSEPulse Biosciences76.95%SRDXSurmodics96.63%Insider OwnershipCompanyInsider OwnershipLUNGPulmonx6.80%OFIXOrthofix Medical1.30%PLSEPulse Biosciences71.50%SRDXSurmodics8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLUNGPulmonx25040.26 million37.52 millionOptionableOFIXOrthofix Medical1,61639.18 million38.67 millionOptionablePLSEPulse Biosciences14067.27 million19.17 millionOptionableSRDXSurmodics45014.30 million13.03 millionOptionableLUNG, OFIX, SRDX, and PLSE HeadlinesRecent News About These CompaniesCalifornia State Teachers Retirement System Boosts Stake in Surmodics, Inc. (NASDAQ:SRDX)June 8, 2025 | marketbeat.comQuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?June 6, 2025 | msn.comZacks Research Has Negative Outlook of Surmodics Q3 EarningsMay 31, 2025 | marketbeat.comWhy Is SurModics (SRDX) Up 6% Since Last Earnings Report?May 30, 2025 | zacks.comWhat is Zacks Research's Forecast for Surmodics Q2 Earnings?May 30, 2025 | marketbeat.comPhocas Financial Corp. Purchases 15,534 Shares of Surmodics, Inc. (NASDAQ:SRDX)May 28, 2025 | marketbeat.comSurmodics, Inc. (NASDAQ:SRDX) Shares Purchased by Squarepoint Ops LLCMay 27, 2025 | marketbeat.comEquities Analysts Set Expectations for Surmodics Q3 EarningsMay 27, 2025 | marketbeat.comSurmodics, Inc. (NASDAQ:SRDX) Shares Bought by Deutsche Bank AGMay 26, 2025 | marketbeat.comAlpine Global Management LLC Takes $1.98 Million Position in Surmodics, Inc. (NASDAQ:SRDX)May 25, 2025 | marketbeat.comSoleus Capital Management L.P. Trims Stock Holdings in Surmodics, Inc. (NASDAQ:SRDX)May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $4.99 Million Stock Holdings in Surmodics, Inc. (NASDAQ:SRDX)May 20, 2025 | marketbeat.comSurmodics, Ballinasloe, offers production operator opportunitiesMay 16, 2025 | advertiser.ieAre Options Traders Betting on a Big Move in Surmodics Stock?May 2, 2025 | msn.comSRDX Stock Down Following Q2 Earnings Miss, Gross Margin ContractsMay 1, 2025 | zacks.comSurmodics stock takes another hit on Q2 miss and 2025 guidanceApril 30, 2025 | massdevice.comSurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to SayApril 30, 2025 | zacks.comSurModics (SRDX) Reports Q2 Loss, Misses Revenue EstimatesApril 30, 2025 | zacks.comSurmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial GuidanceApril 30, 2025 | businesswire.comA Look at Surmodics's Upcoming Earnings ReportApril 30, 2025 | benzinga.comSurmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30April 28, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsSouthwest Airlines: Short Interest Plunges—Should You Buy?By Gabriel Osorio-Mazilli | June 17, 2025View Southwest Airlines: Short Interest Plunges—Should You Buy?LUNG, OFIX, SRDX, and PLSE Company DescriptionsPulmonx NASDAQ:LUNG$2.75 +0.04 (+1.48%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.95 +0.20 (+7.31%) As of 06/18/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Orthofix Medical NASDAQ:OFIX$10.35 -0.17 (-1.62%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$10.35 0.00 (0.00%) As of 06/18/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.Pulse Biosciences NASDAQ:PLSE$15.05 +0.01 (+0.07%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$15.04 -0.02 (-0.10%) As of 06/18/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Surmodics NASDAQ:SRDX$29.14 +0.09 (+0.31%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$29.12 -0.03 (-0.09%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
